MedTrace Logo

Stable Isotopes- Adults With Obesity

NCT07020741 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-04-29

No results posted yet for this study

Summary

In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes. Repeated blood, breath, urine, and muscle biopsies will be taken. In the second arm, participants will consume 1 drink containing 75g glucose, labeled with two stable isotopes of glucose. Periodic blood and breath will be taken over three hours.

Conditions

  • Obese Patients (BMI ≥ 30 kg/m²)
  • Glucose Metabolism
  • Protein Metabolism

Interventions

PROCEDURE

Indispensable Amino Acid Oxidation

Participants will ingest six hourly meals designed to provide 50% of the daily intake of 1.1 g·kgLBM. Additional energy (1.5x daily resting metabolic rate), carbohydrate (55%), and fat (35%) will be provided in beverages and protein-free cookies (for palatability). The first drink will contain priming doses of NaH13CO2 (0.176 mg·kg-1), \[13C\]phenylalanine (1.86 mg·kg-1), \[2H5\]phenylalanine (0.34 mg·kg-1) with all subsequent drinks containing 1.2 mg·kg-1 \[13C\]phenylalanine and 0.51 mg·kg-1 \[2H5\]phenylalanine.

PROCEDURE

Stable Isotope Oral Glucose Tolerance Test

Participants will consume a 75g glucose drink dissolved in 250 ml of water enriched with \[6,6\_2H2\]glucose and \[13C6\]glucose.

Sponsors & Collaborators

  • University of Illinois at Urbana-Champaign

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-12
Primary Completion
2026-08-30
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07020741 on ClinicalTrials.gov